propranolol has been researched along with Sarcoma in 2 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Sarcoma: A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Standard chemotherapy for soft tissue sarcomas has shown limited efficacy." | 5.56 | The β-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study. ( Azzariti, A; Di Fonte, R; Fucci, L; Garofoli, M; Guida, M; Porcelli, L; Strippoli, S; Volpicella, M, 2020) |
| "Standard chemotherapy for soft tissue sarcomas has shown limited efficacy." | 1.56 | The β-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study. ( Azzariti, A; Di Fonte, R; Fucci, L; Garofoli, M; Guida, M; Porcelli, L; Strippoli, S; Volpicella, M, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Porcelli, L | 1 |
| Garofoli, M | 1 |
| Di Fonte, R | 1 |
| Fucci, L | 1 |
| Volpicella, M | 1 |
| Strippoli, S | 1 |
| Guida, M | 1 |
| Azzariti, A | 1 |
| Lee, ATJ | 1 |
| Huang, PH | 1 |
| Pollack, SM | 1 |
| Jones, RL | 1 |
2 other studies available for propranolol and Sarcoma
| Article | Year |
|---|---|
The β-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study.
Topics: Adrenergic beta-Antagonists; Cell Line, Tumor; Cyclooxygenase 2; Doxorubicin; Drug Resistance, Neopl | 2020 |
Drug repositioning in sarcomas and other rare tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Repositioning; Humans; P | 2016 |